Management members

Lynne Powel

CEO

Ms. Powell has more than 25 years’ experience in the biopharmaceutical/ biotechnology industry.  Prior to DRGT she served as Chief Commercial Office at BioCryst, an emerging biotechnology company focused on commercializing innovative small molecules. Before this, she was Senior Vice President, North America, at CSL Behring.  Throughout her 17-year career at CSL Behring, she assumed increasing responsibilities within the R&D and commercial functions of the organization. Lynne has significant global experience serving as Vice President, Global Commercial Development and Head of Business Development & European Marketing, Head of Project and Portfolio Management and Head of Clinical Research. Ms. Powell also held positions within Glaxo Wellcome’s commercial strategy and clinical research organizations.

Lyenne Powell


Genovéva Filipcsei, PhD

Chief IP Officer

Dr. Filipcsei has an MSc in colloid chemistry and a PhD in chemistry. She joined the DRGT Team in 2008. Genovéva is the former CSO of NanGenex. Currently she holds the position of Chief IP Officer. Previously, she served as a senior lecturer at Budapest University of Technology and Economics at the Faculty of Chemical engineering and bioengineering. She held a postdoctoral fellowship of Katholieke Universiteit Leuven and a research fellowship of Suzuki Foundation at National Institute of Advanced Industrial Science and Technology (AIST), Research Centre of Advanced Bionics Bio-Nanomaterials Team in Tsukuba. She received the Bolyai plaquette in 2007 and the Polanyi Price of Hungarian Academy of Sciences in 2009. Dr. Filipcsei was the winner of the Young Inventor of 2005 award in Hungary. She is the co-author of 44 publications in international journals, 25 patent applications, 12 international lectures and 45 conference posters. 

Dr. Genovéva Filipcsei

Gábor Heltovics

President, Druggability Technologies Holdings Ltd., Research

Mr. Heltovics holds Master's degrees in Biology (1995), Chemistry (1995), and Business Administration (MBA, 2003). He is a seasoned entrepreneurial senior executive with extensive R&D and general management experience in this field in the US, UK, and EU. He has a successful track record of innovation management and technology platform development in major multinational corporations such as Procter & Gamble and Coca-Cola, as well as SME Bio-pharmaceutical companies such as SOLVO Biotechnology.

Dr. Glavinas Hristos

Hristos Glavinas

CSO

Dr. Glavinas is the Chief Scientific Officer  at NanGenex. Previously he held the position of Director of Pharnaceutical Development. Before joining the DRGT Team he served as  Principal Scientist, Head of Research and Development at Solvo Biotechnology. Prior he worked as visiting scientist at the Children’s Hospital Medical Center, Cincinnati, OH, USA. He completed his PhD studies in molecular biology at Albert Szent-Györgyi Medical University, Szeged, Hungary. He is the author of 23 peer reviewed research papers and presented his work at numerous international conferences. 




 

Katalin Ferenczi

Managing Director & Business Development

Mrs. Ferenczi graduated as a biomedical engineer at University of Miami. After returning to Budapest, for a short period of time, she worked at Genpact, a formerly GE owned company, that has established itself as one of Europe’s business services and technology solutions providers. Before joining NanGenex - Member of the Druggability Technologies Group (DRGT), she held a senior business development position at SOLVO Biotechnology (2006 - 2010) and was responsible for the European sales operation of the company.

Katalin Ferenczi

Druggability Technologies USA

John E. Friend II., M.D

Chief Medical Officer 

Dr. Friend brings more than 16 years of leadership experience in the biopharmaceutical industry to DRGT USA. Previously, he was Chief Medical Officer of Cellectar Biosciences, Inc. where he was instrumental in the planning and execution of a number of oncology development programs, including rare pediatric and adult hematologic cancers. Prior to that, Dr. Friend served as Senior Vice President of Research and Development at Helsinn Therapeutics (U.S.), Inc. leading its research and development, clinical, medical affairs and regulatory affairs divisions. Prior to his time at Helsinn, Dr. Friend held executive responsibility for clinical research, medical affairs, pharmacovigilance and risk management at various pharmaceutical companies including Akros Pharma, Actavis, Alpharma, Hospira and Abbott. He completed post-graduate residency program in family medicine and subsequently served as Clinical Director and faculty attending physician at Cabarrus Family Medicine Residency Program in North Carolina. After obtaining an undergraduate degree in Chemistry from Southern Methodist University, Dr. Friend earned his medical degree from UMDNJ-Robert Wood Johnson Medical School (now Rutgers, RWJMS).

Dr. Elizabeth Manning Duus

Executive Director, Clinical Development 

Dr. Duus brings 13 years of clinical research experience in the biopharmaceutical industry to DRGT USA. Most recently, she served as Senior Director, Clinical Research & Strategy at Helsinn Therapeutics (U.S.), Inc.  Over the past 8 years at Helsinn, Dr. Duus has led the clinical strategy for oncology-related compounds in development, contributed to global regulatory engagements, supported clinical operations and biostatistics, managed medical writing activities, and oversaw investigator-initiated and collaborative studies in the US. She has also held positions of increasing responsibility at Akros Pharma Inc and Avantix Laboratories.  After receiving an undergraduate degree in biology from the University of Delaware, Dr. Duus earned her PhD in pharmacology and molecular sciences from the Johns Hopkins University School of Medicine.

Dominic P. Capone

Senior Director, Clinical Development 

Mr. Capone brings 24 years of clinical operations and clinical research experience in the biopharmaceutical industry to DRGT USA.  Most recently, he served as Senior Director Clinical Operations & Program Management at Antares Pharma, Inc.  Over the past 9 years Dominic has successfully led numerous products through the 505b2 pathway from IND to NDA submission.  Managing deliverables from multiple disciplines including Device, CMC, Clinical Research, and Regulatory.  Dominic also managed all aspects of clinical trials, Phase 1 thru Phase 3, including clinical operations, data management, and clinical supplies management.  He previously held positions in clinical operations and clinical supplies management at Akros Pharma Inc and Omnicare Pharmaceuticals Inc.  Prior to a career in the pharmaceutical industry Dominic served honorably in the United States Air Force as an Aerovac Medical Technician supporting military and humanitarian missions around the world.